Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. AML study reports high response rates with combination targeted therapy

    ... Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete ...

    Article last updated 12/12/2017 - 8:29am.

  2. Diagnosis and Treatment of Aplastic Anemia

    ... initial IST, with randomized studies underway. In the refractory setting, several therapeutic options exist, with improving ...

    Research Article last updated 12/06/2017 - 8:45am.

  3. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

    ... Limited therapies exist for patients with refractory and relapsed (RR) higher-risk myelodysplastic syndromes ...

    Research Article last updated 11/02/2016 - 9:17am.

  4. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

    ... therapy (IST) or IST and eltrombopag, and 10 IST- refractory patients who had received eltrombopag only, focusing on ...

    Research Article last updated 10/23/2017 - 11:19am.

  5. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... responses are often short-lived. In fact, many ESA- refractory patients harbor defects in late-stage erythropoiesis downstream ...

    Research Article last updated 10/23/2017 - 11:08am.

  6. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... in treating patients with relapsed or refractory acute myeloid leukemia. An immune cell is a type of blood cell ... enrolled are those patients with active relapsed or refractory CD123+ acute myeloid leukemia (AML) de novo , or ... disease (increased bone marrow blasts ) Refractory AML is defined as patients that have not achieved a CR after 2 ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  7. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... responses are often short-lived. In fact, many ESA- refractory patients harbor defects in late-stage erythropoiesis downstream ...

    Research Article last updated 10/02/2017 - 10:10am.

  8. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

    ... therapy (IST) or IST and eltrombopag; 10 IST- refractory patients who had received eltrombopag only), focusing on ...

    Research Article last updated 10/02/2017 - 9:40am.

  9. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... without del(5q), but its efficacy in patients clearly refractory to erythropoiesis-stimulating agents (ESA) is not known. We ... consecutive lower-risk non-del(5q) MDS patients with anaemia refractory to ESA and treated with LEN in a compassionate programme, 20 of whom ...

    Research Article last updated 04/24/2012 - 2:47pm.

  10. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia

    ... from 2003-2010 in treatment-naïve, relapsed, and refractory SAA in three separate research protocols at the National ... Primary outcome was hematologic response at 6 months. For refractory disease, patients were randomized between rabbit ATG plus ... in SAA but best results are obtained in the relapsed and refractory settings. The trials were registered at www.clinicaltrials.gov ...

    Research Article last updated 11/16/2011 - 1:57pm.